Rhumatologie. Canakinumab: un traitement prometteur [Canakinumab: a promising treatment in rheumatology].

Détails

ID Serval
serval:BIB_49E2B4293272
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Rhumatologie. Canakinumab: un traitement prometteur [Canakinumab: a promising treatment in rheumatology].
Périodique
Revue Médicale Suisse
Auteur⸱e⸱s
Fabreguet I., So A.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
2012
Volume
8
Numéro
323
Pages
57-60
Langue
français
Notes
Publication types: English Abstract ; Journal ArticlePublication Status: ppublish
Résumé
In auto-inflammatory diseases, the role of the inflammasome and the interleukine IL-1beta has recently been shown. Thus, the physiopathology of rare diseases as Cryopyrin-associated periodic syndrome (CAPS) is better understood. In the era of biologics, new treatments targeting IL-1 have been developped. Canakinumab is a fully humanized monoclonal antibody inhibiting specifically IL-1beta Clinical studies have shown its efficacy on clinical symptoms and on inflammatory markers in patients with rare diseases such as CAPS or idiopathic juvenile arthritis, but also in more common rheumatic conditions like gout. Canakinumab has been approved in Switzerland only for the treatment of CAPS. Studies evaluating its effect on cardiovascular diseases are ongoing.
Mots-clé
Antibodies, Monoclonal/therapeutic use, Arthritis, Gouty/drug therapy, Arthritis, Juvenile Rheumatoid/drug therapy, Biological Markers/blood, Cryopyrin-Associated Periodic Syndromes/drug therapy, Cryopyrin-Associated Periodic Syndromes/immunology, Humans, Inflammasomes/immunology, Inflammation/immunology, Interleukin-1beta/immunology, Rheumatic Diseases/diagnosis, Rheumatic Diseases/drug therapy, Rheumatology/trends, Treatment Outcome
Pubmed
Création de la notice
06/06/2012 18:18
Dernière modification de la notice
20/08/2019 13:57
Données d'usage